Deep Knowledge Ventures Makes First Investment In Space
Deep Knowledge Ventures and Transplanetary to Create Machine Learning Program to Produce Real-Time Analysis of Global Space Ecosystem and Intelligent Investment Recommendations
London, UK - September 4, 2014 (www.investorideas.com newswire) Deep Knowledge Ventures (DKV), a Hong Kong-based venture capital fund that utilizes Artificial Intelligence software to make cutting edge investment decisions, announced today its first investment in aerospace. DKV has acquired a stake in Transplanetary, a Silicon Valley based space development company that is on a mission to make the global space sector more accessible and attractive to investors.
DKV and Transplanetary are working closely to develop SPOCK (Space Program Ontologically Computed Knowledge), a machine learning program capable of producing real-time analysis of the global space ecosystem, which it will use to make intelligent investment recommendations. SPOCK will analyze publicly available data on over 1,000 organizations including commercial space companies, government space agencies, NGOs and academic research labs. The data that SPOCK develops will feed into a new dynamic roadmap of space exploration and settlement enabling investors to identify the optimum investment targets, analysts to monitor industry growth, industry professionals to target supply chain partners and space enthusiasts to engage in what will become by default the mapping of the human civilization's space program.
SPOCK joins DKV's family of sector specific machine learning programs that includes VITAL (Validating Investment Tool for Advancing Life Sciences), a system capable of making investment recommendations in the life science sector. In an industry first, VITAL was appointed to DKV's Board of Directors in May 2014.
"This is an exciting development for DKV, our investment strategy has always been to leverage our expert understanding of complex investments, such as biotech and aerospace. Today, we continue this challenging work through our partnership with Transplanetary. With the help of our technology and additional investment, the Transplanetary team will be able to successfully deliver a truly indispensable product for the entire industry," said Dmitry Kaminskiy, DKV Senior Partner.
Jim Keravala, CEO of Transplanetary stated: "Human settlement of space is not going to happen without aligning the needs of investors and companies with the visions of the future. Transplanetary will connect these needs into a single system."
Like VITAL, SPOCK will be able to provide intelligent investment recommendations, taking into account factors such as technological maturity and market outlook. DKV has already used VITAL to make several investment recommendations; Pathway Pharmaceuticals, Limited in Hong Kong and InSilico Medicine in Baltimore. Both stocks are performing well and the expected ROI is very high. DKV has a long-term goal of developing the software to a point it is capable of autonomously allocating an investment portfolio.
For more information contact:
Henry Liao, Deep Knowledge Ventures firstname.lastname@example.org
Transplanetary is a Silicon Valley-based space development company on a mission to seed new in-space markets and make the global space sector more investable. As a first step in a long-term roadmap, it is developing an AI-powered web intelligence platform that will give space investors, commercial space community and space enthusiasts a real-time insight into the global space ecosystem as it stands today and its planned trajectory all the way until 2112. The Transplanetary project will be see its debut at the Next Giant Leap Conference in November 2014. Receive forthcoming announcements by registering interest at http://www.transplanetary.com.
About Deep Knowledge Ventures
Deep Knowledge Ventures is a Hong Kong-based venture fund management company focused on deploying machine learning to accelerate progress in high-impact fields like biotechnology and now space. It routinely makes mid- to long-term investments at an early stage. DKV's investment portfolio spans biotechnology, regenerative medicine, oncology, drug discovery, bioinformatics and personalized medicine. For more information, please visit http://www.deepknowledgeventures.com
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.